Bull Case

Positive late-stage clinical readouts and regulatory progress drive partnering or approval momentum, lifting COYA versus development-stage peers that still face binary trial risk.

A successful monetization event or non-dilutive financing extends runway, reducing capital pressure and allowing COYA to advance programs while weaker peers remain funding-constrained.

Improved investor confidence from de-risking milestones supports a higher valuation multiple, as peers with similar pipelines typically re-rate only after clear efficacy and safety validation.

Base Case

Clinical development advances incrementally but remains pre-commercial, so COYA grows value through milestones while peers with approved assets continue to generate revenue and cash flow.

Ongoing operating losses and negative cash generation require periodic financing, which limits operating flexibility and keeps COYA structurally behind better-capitalized peers.

The pipeline retains optionality, but without decisive data or partnership terms, COYA’s forward profile stays dependent on event timing rather than durable commercial traction.

Bear Case

Clinical setbacks or regulatory delays would sharply reduce program value, as development-stage peers with clearer data would absorb capital and attention more effectively.

Persistent losses and extreme leverage metrics increase dilution or restructuring risk, which can compress equity value faster than peers with stronger balance sheets.

If financing windows close before major catalysts, COYA may be forced to slow development or seek unfavorable terms, materially weakening its competitive position.

Overall Score

COYA’s forward profile is dominated by binary clinical and financing outcomes, leaving meaningful upside from de-risking but a base case still constrained by losses and capital dependence versus peers.